Summary
New drugs for treating hepatitis C have considerably increased the probability of being cured. Treatment uptake, however, is still low. The objectives of this study were to analyse the impact of initiatives that may increase the proportion of infected people on treatment and interventions aimed at reducing the incidence of new infection among people who inject drugs. A compartmental model for Norway was used to simulate hepatitis C and related complications. We analysed 2 different screening initiatives aimed to increase the proportion of infected people on treatment.
Interventions aiming at reducing the hepatitis C incidence analysed were opioid substitution therapy (OST), a clean needle and syringe programme and a combination of both. The most cost-effective strategy for increasing hepatitis C treatment uptake was screening by general practitioners while simultaneously allowing for all infected people to be treated. We estimated that this intervention reduces the incidence of hepatitis C by 2030 by 63% compared with the current incidence. The 2 harm reduction strategies both reduced the incidence of hepatitis C by about 70%. Combining an increase in the current clean needles and syringe programme with OST was clearly the most cost-effective option. This strategy would reduce the incidence of hepatitis C by 80% compared with the current incidence by 2030. Thus, interventions to reduce the burden and spread of hepatitis C are cost-effective. Reaching the WHO target of a 90% reduction in hepatitis C incidence by 2030 may be difficult without combining different initiatives.
K E Y W O R D S
costs and cost analysis, harm reduction, hepatitis, mass screening, resource allocation
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2018 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd a slight increase, including Norway, although recent estimates indicate that only about 10% of Norwegian patients with hepatitis C had been cured before the introduction of sofosbuvir in 2014. 12 The proportion of infected people on treatment stands in sharp contrast to the WHO goals of reducing the incidence of hepatitis C by 90% and mortality by 65% by 2030 (http://apps.who.int/iris/ bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1).
To reach this goal, the uptake to hepatitis C virus (HCV) treatment must increase substantially; the question is, how? In Norway, most hepatitis C patients have been infected through injecting drugs. 13, 14 Therefore, to increase the number of individuals treated, screening initiatives would likely be best aimed at these populations.
There are several possible strategies available aimed at reducing the burden of hepatitis C. High-quality evidence of efficacy of these strategies, such as systematic reviews of randomized controlled trials are, however, limited in number. Interventions such as opioid substitution therapy (OST) and needle and syringe programmes (NSP) have several important health outcomes including reduced incidence of hepatitis, although the evidence is limited. Given the high prices of the new medications, it is important to assess whether interventions that increase uptake of these medications are as cost-effective as other strategies, such as harm reduction initiatives. Thus, there is an urgent need to combine the best available evidence on potential initiatives and assess which of these are the most cost-effective.
Birth cohort screening has been analysed in several jurisdictions previously, [15] [16] [17] but is not a relevant policy for a Norwegian setting as the prevalence of hepatitis C is similar in all adult cohorts born after 1950. More broad screening alternatives have been analysed from both a United States and Canadian setting. 18, 19 Both these analyses found screening likely to be cost-effective.
Previous health economic evaluations of interventions to reduce the hepatitis C burden have mainly focused on hypothetical scenarios, without taking into account the cost of programmes to increase the number of people tested and treated. 3, 20, 21 There is a need to assess which realistic alternatives can be performed and what kind of health impact these may have among people who either inject or have previously injected drugs. These analyses should, as far as possible, be based on evidence of the efficacy of new drugs, but also of the efficacy of the interventions applied to increase treatment among patients.
The primary objective of this study was therefore to evaluate the cost-utility of different interventions that may reduce the burden of hepatitis C in the Norwegian population, focusing on screening to increase HCV treatment uptake and harm reduction initiatives.
Secondary objectives included assessing to what extent the interventions applied could facilitate elimination defined as a 90% reduction of hepatitis C incidence in Norway.
| ME THODS
We based our analyses on a compartmental Markov model which has been used in modelling the burden of hepatitis C in Norway and the cost-effectiveness of drugs for patients with hepatitis C.
1,10
Transition probabilities and uncertainty surrounding these have been thoroughly described in previous publications. TA B L E 1 Reductions in incidence and mortality by 2030
In the analyses, we assumed that all patients on hepatitis C treatment would use the drugs that were shown to be the most cost-effective for Norway at the end of 2016. 10 The assumption underlying the current analyses therefore suggests that all patients with genotype 1 used the combination treatment comprising paritaprevir, ritonavir, ombitasvir and dasabuvir, with subgroups of patients with cirrhosis or genotype 1A receiving ribavirin in addition.
We also assumed that genotype 2 patients receive sofosbuvir and ribavirin and genotype 3 patients sofosbuvir, peginterferon alpha 2a and ribavirin.
In this analysis, we analysed 2 different screening strategies; Data on the effect and cost of each treatment option were based on a wide range of different sources (see Appendix Table A2 ). Where randomized controlled trial data were available, these were used for informing the effect of interventions in the model. Where randomized controlled trials were not available, evidence was based on systematic reviews of observational studies.
In 2016, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) issued a report on hepatitis C among drug users in Europe. 27 In the report, evidence on current status and the efficacy of interventions have been summarized. In the report, the effect of OST was indicated to be OR = 0.41 (0.21-0.82) based on a meta-analysis by Turner et al 28 In the model, this estimate was first recalculated into a relative risk and thereafter applied based on the assumption that 50% of the injecting drug users may be included in an OST programme.
The effect of a NSP was also available from the EMCDDA report. 27 Data were presented comparing more than a 100% coverage vs less than a 100% coverage with an adjusted odds ratio of 0.48 (0.24-0.93). In Norway, we have estimated coverage of around 75% (see Appendix), indicating that we would expect to see about half as many infections if a scale-up was introduced.
Results similar to those found in the EMCDDA report have also been found by others, for instance, Bluthenthal et al 29 Current
volume of clean needles and syringes handed out is used as a proxy for all clean user equipment as a definition of the current situation. If other user equipment is handed out to a less extent than needles and syringes, we may underestimate the effect of expanding the programme. Similarly, there is uncertainty, both about the extent of the NSP programme in Norway today, the realism of an increase beyond the current coverage, and the effect of such an increase on the incidence of hepatitis C. We therefore conducted sensitivity analyses looking at which interventions would be most cost-effective if we assume only half of the effect shown in the EMCDDA report. The only RCT we found concerning screening at GP offices is by Roudot-Thoraval et al 33 The increase in number screened in the Roudot-Thoraval trial resulted in an increase in number of positive hepatitis C test (RR = 1.37) which was close to that reported in a much larger, but nonrandomized study by Litwin et al reporting an RR of 1.26. 34 We based our analyses on the RCT, to be consistent with our goal of including RCTs whenever possible. For the screening at GP strategy, we assumed all GPs in Norway were sent a letter informing them about which questions to ask to test those with a previous injection history for hepatitis C. For screening at facilities, we assumed an increase in the number of nurses available to recruit attendees for screening at a rate of one nurse per 20 treated.
We assumed that the interventions modelled were started at the beginning of 2016. Within-cycle correction was applied using
Simpson's 1/3rd rule, which has proven to be superior to, for example, half-cycle correction. 35 As described in previous publications, the model was based on data from 1975 and onwards. 1, 10 Model of transmission was performed until 2030, 1 while health effects for all who acquire disease by 2030 will be modelled until these individuals die or are 100 years old. 10 The model was made probabilistic by representing all uncertain variables in the model by probability distributions. The specification of distributions is given as part of the specification of each parameter (Appendix Tables A1 and A2 ). All uncertain input parameters were simulated with 1000 iterations, and the model was subsequently run 1000 times using these different input parameters.
The cost-effectiveness of interventions provided in Norway is traditionally evaluated against thresholds of cost-effectiveness that are relatively close to the Norwegian gross domestic product per person. For 2015, this was reported to be around NOK 600 000. In a recent review of decisions made based on cost-utility in Norway, NOK 700 000 per QALY gained was the reported average threshold. We therefore used this in our analyses. 36 Other thresholds suggested for Norway have varied between NOK 275 000 and NOK 1.2 million. For calculations of net health benefit, we assumed NOK 700 000 per QALY as the cost-effectiveness threshold. Based on this threshold, the most cost-effective strategy was defined to be the strategy that maximized net health benefit.
| RE SULTS
The different interventions are expected to result in incidence reductions of between 55% and 74% in the years up to 2030, while combinations of interventions may decrease incidence by up to 80% (Table 1 and Appendix Figures A1 and A2) . Over a lifetime perspective for all current, future and previous PWID in the period up to 2030 increases in life expectancy ranges between 57 and 57 000
( Table 2 ). The largest reduction in incidence (74% by 2030) and largest gain in quality-adjusted life expectancy due to a single initiative would be expected if the NSP was increased to more than 100%
coverage.
The health gains of some initiatives are substantial, but so are the costs, too. In some instances, however, the interventions may reduce so much of the future disease burden that future cost implications are negative, implying that the intervention costs are less than what will be saved in future treatment costs (Table 2) . When If we look at the different harm reduction and screening initiatives compared to each other, we find the combination of NSP and OST will be the most cost-effective. In Figure 3 , we clearly see that among the interventions below the WTP line, the combination of OST and NSP has the longest distance to the line, which also implies having the highest incremental net benefit. Combining the uncertainties around all these interventions also shows that the probability of the combination of OST and NSP being the most cost-effective is 97% at a threshold of NOK 700 000 per QALY.
TA B L E 2 Incremental costs and effects of screening sorted by increasing effectiveness
Regarding scale-up of an NSP programme, there are several uncertainties. For instance, the current level of NSP coverage in Norway and the transferability of effect from other jurisdictions.
We have therefore performed the harm reduction analyses with only half of the NSP effect. These analyses show that if the effect of NSP is halved, the combination of OST and NSP is still the most costeffective, but we are now only 62% certain, while OST alone has a 32% probability of being the most cost-effective ( Figure 4 ).
| D ISCUSS I ON
Our results show that both harm reduction and screening initiatives combined with treatment are cost-effective in a Norwegian ICER, incremental cost-effectiveness ratio; INHB, Incremental net health benefit (at threshold of NOK 700 000 per QALY); dominated strategies are less efficacious and more costly than the most cost-effective strategy, dominant signifies a strategy with higher expected QALYs and lower expected costs than all other options; NOK, Norwegian kroner; NSP, needles and syringes programme; OST, opioid substitution therapy; QALY, quality-adjusted life year. Vickerman et al 39 conducted a study exploring the impact of NSP and OST in a UK setting. The analysis was based on the same metaanalysis as that used in our present analyses. 28 In their analyses, they found that scaling up NSP and OST could reduce HCV prevalence considerably, although this required high coverage.
F I G U R E 2
The present analysis has several limitations. The most impactful is the lack of randomized evidence of the efficacy of interventions to reduce the hepatitis C burden. Among interventions analysed, most have been proven effective in a randomized controlled trial, but few have been tested for reproducible efficacy in different RCTs. Given that nonrandomized evidence has some inherent bias related to design, the results have to be interpreted with this limitation in mind.
In addition, in cases where only one RCT has been published, such as for screening at GP offices, we cannot be certain of the transferability of the effect to other jurisdictions.
Some of the interventions we analysed were specifically aimed at hepatitis C, while others had a broader scope, and thereby also have effects on other outcomes. For instance would it be reasonable to assume that an OST would also reduce the number of overdoses, which, in turn, considerably impact both health and resource use.
The exclusion of these effects is a clear limitation of the analyses from an overall perspective. Note, however, that the underlying mortality is assumed to be higher among injecting drug users than among previous drug users, which would make this limitation less impactful. In addition, some of the interventions may not be carried out exactly as we assumed in our analysis. For instance, although screening at GP offices would mainly be aimed at previous injecting drug users in Norway, it would probably also be aimed at some other high-risk groups as well. Since current and previous injecting drug Although this estimate may be rough, we have identified other sources, such as an online firm selling clean equipment (www.
brukerutstyr.no), which reports prices somewhat lower for only the cost of the equipment only, without including other costs. Hence, the estimate used in our analyses is probably not too far off from reality.
In general, one can never be certain as to whether studies performed in one jurisdiction are valid in another. All studies of the effect of the different interventions used in this cost-utility analysis are all from different countries and none of these are from the area we studied (Norway). Hence, all results rest on the assumption of the transferability of results to a Norwegian setting.
In conclusion, harm reduction initiatives and screening for hepatitis C are cost-effective strategies to reduce burden of hepatitis C in a Norwegian setting, but reaching WHO targets is not likely without combining several interventions.
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